Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$2.16 USD
-0.06 (-2.70%)
Updated May 17, 2024 04:00 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
Cresco Labs Inc. [CRLBF]
Reports for Purchase
Showing records 101 - 120 ( 124 total )
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
2Q22 In-Line, Brand Strong but Verticality Pressures 2H22, PT to $7
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Q222 In Line but Mgmts H222 Outlook Well Below Consensus and Our Estimates, Progress Towards Closing CCHW Acquisition Positive
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
EBITDA Slightly Above Expectations; Columbia Care Acquisition On-Track
Provider: VENTUM CAPITAL MARKETS
Analyst: ZANDBERG J
Company: Cresco Labs Inc.
Industry: Medical - Products
Cannabis Industry Update: 2Q22 Week II Earnings Preview
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
U.S. Cannabis 2Q22 Preview: Macro Impacting NT, Legislative Progess Warming
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Operating Income Gaining Investor Interest As Industry Matures
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Consumer Access Key - Opening More Retail Licenses
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cresco Labs Inc.
Industry: Medical - Products
NJ Adult-Use Cannabis Update: New Recreational Stores Added to Begin Sales
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
1Q22 In-Line, Leveraging Brand Success Ahead of Acquisition Close
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
In Line Q122 Results Demonstrate Market Share Gains, Awaiting Details on Progress with Possible Divestitures
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
Revenue Above Expectations as Acquisition of Columbia Care Remains On-Track
Provider: VENTUM CAPITAL MARKETS
Analyst: ZANDBERG J
Company: Cresco Labs Inc.
Industry: Medical - Products
Cannabis Earnings 1Q22: Week III Preview
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: CAOA Federal Reform Update and Alcohol Tier Model in Cannabis
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: NJ and NY Conversion Catalyst Fueling M&A
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Accretive? TBD. Irony as Major Acquisition Likely to Cause Divestitures to Become CLs Buzz Word for the NTM. Q421 Underwhelms Muted Expectations
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
4Q21 Soft, Transformative Acquisition of Columbia Care, Lower PT to $12
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S